BACKGROUND: SPECT/CT improves localization of single photon-emitting radiopharmaceuticals. OBJECTIVE: To determine the utility of SPECT/CT in children with papillary thyroid carcinoma. MATERIALS AND METHODS: 20 SPECT/CT and planar studies were reviewed in 13 children with papillary thyroid carcinoma after total thyroidectomy. Seven studies used I-123 and 13 used I-131, after elevating TSH by T4 deprivation or intramuscular thyrotropin alfa. Eight children had one study and five children had two to four studies. Studies were performed at initial post-total thyroidectomy evaluation, follow-up and after I-131 treatment doses. SPECT/CT was performed with a diagnostic-quality CT unit in 13 studies and a localization-only CT unit in 7. Stimulated thyroglobulin was measured (except in 2 cases with anti-thyroglobulin antibodies). RESULTS: In 13 studies, neck activity was present but poorly localized on planar imaging; all foci of uptake were precisely localized by SPECT/CT. Two additional foci of neck uptake were found on SPECT/CT. SPECT/CT differentiated high neck uptake from facial activity. In six studies (four children), neck uptake was identified as benign by SPECT/CT (three thyroglossal duct remnants, one skin contamination, two by precise anatomical CT localization). In two children, SPECT/CT supported a decision not to treat with I-131. When SPECT/CT was unable to identify focal uptake as benign, stimulated thyroglobulin measurements were valuable. In three of 13 studies with neck uptake, SPECT/CT provided no useful additional information. CONCLUSION: SPECT/CT precisely localizes neck iodine uptake. In small numbers of patients, treatment is affected. SPECT/CT should be used when available in thyroid carcinoma patients.
BACKGROUND: SPECT/CT improves localization of single photon-emitting radiopharmaceuticals. OBJECTIVE: To determine the utility of SPECT/CT in children with papillary thyroid carcinoma. MATERIALS AND METHODS: 20 SPECT/CT and planar studies were reviewed in 13 children with papillary thyroid carcinoma after total thyroidectomy. Seven studies used I-123 and 13 used I-131, after elevating TSH by T4 deprivation or intramuscular thyrotropin alfa. Eight children had one study and five children had two to four studies. Studies were performed at initial post-total thyroidectomy evaluation, follow-up and after I-131 treatment doses. SPECT/CT was performed with a diagnostic-quality CT unit in 13 studies and a localization-only CT unit in 7. Stimulated thyroglobulin was measured (except in 2 cases with anti-thyroglobulin antibodies). RESULTS: In 13 studies, neck activity was present but poorly localized on planar imaging; all foci of uptake were precisely localized by SPECT/CT. Two additional foci of neck uptake were found on SPECT/CT. SPECT/CT differentiated high neck uptake from facial activity. In six studies (four children), neck uptake was identified as benign by SPECT/CT (three thyroglossal duct remnants, one skin contamination, two by precise anatomical CT localization). In two children, SPECT/CT supported a decision not to treat with I-131. When SPECT/CT was unable to identify focal uptake as benign, stimulated thyroglobulin measurements were valuable. In three of 13 studies with neck uptake, SPECT/CT provided no useful additional information. CONCLUSION: SPECT/CT precisely localizes neck iodine uptake. In small numbers of patients, treatment is affected. SPECT/CT should be used when available in thyroid carcinomapatients.
Authors: Katherine S Kolbert; Keith S Pentlow; Joel R Pearson; Arif Sheikh; Ronald D Finn; John L Humm; Steven M Larson Journal: J Nucl Med Date: 2007-01 Impact factor: 10.057
Authors: K Tharp; O Israel; J Hausmann; L Bettman; W H Martin; M Daitzchman; M P Sandler; D Delbeke Journal: Eur J Nucl Med Mol Imaging Date: 2004-06-19 Impact factor: 9.236
Authors: L S Freudenberg; C Frömke; T Petrich; R J Marlowe; W W Koska; W Brandau; E G Eising; E J Knust; A Bockisch; W Jentzen Journal: Exp Clin Endocrinol Diabetes Date: 2009-10-23 Impact factor: 2.949
Authors: S Kohlfuerst; I Igerc; M Lobnig; H J Gallowitsch; I Gomez-Segovia; S Matschnig; J Mayr; P Mikosch; M Beheshti; P Lind Journal: Eur J Nucl Med Mol Imaging Date: 2009-01-24 Impact factor: 9.236
Authors: Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita Journal: Thyroid Date: 2015-07 Impact factor: 6.568
Authors: Sasha R Howard; Sarah Freeston; Barney Harrison; Louise Izatt; Sonali Natu; Kate Newbold; Sabine Pomplun; Helen A Spoudeas; Sophie Wilne; Tom R Kurzawinski; Mark N Gaze Journal: Endocr Relat Cancer Date: 2022-09-07 Impact factor: 5.900